Literature DB >> 34609711

ABCpred: a webserver for the discovery of acetyl- and butyryl-cholinesterase inhibitors.

Aijaz Ahmad Malik1, Suvash Chandra Ojha2, Nalini Schaduangrat1, Chanin Nantasenamat3.   

Abstract

Alzheimer's disease (AD) is one of the most common forms of dementia and is associated with a decline in cognitive function and language ability. The deficiency of the cholinergic neurotransmitter known as acetylcholine (ACh) is associated with AD. Acetylcholinesterase (AChE) hydrolyses ACh and inhibits the cholinergic transmission. Furthermore, both AChE and butyrylcholinesterase (BChE) plays important roles in early and late stages of AD. Therefore, the inhibition of either or both cholinesterase enzymes represent a promising therapeutic route for treating AD. In this study, a large-scale classification structure-activity relationship model was developed to predict cholinesterase inhibitory activities as well as revealing important substructures governing their activities. Herein, a non-redundant dataset constituting 985 and 1056 compounds for AChE and BChE, respectively, was obtained from the ChEMBL database. These inhibitors were described by 12 sets of molecular fingerprints and predictive models were developed using the random forest algorithm. Evaluation of the model performance by means of Matthews correlation coefficient and consideration of the model's interpretability indicated that the SubstructureCount fingerprint was the most robust with five-fold cross-validated MCC of [0.76, 0.82] for AChE and BChE, respectively, and test MCC of [0.73, 0.97]. Feature interpretation revealed that the aromatic ring system, heterocyclic nitrogen containing compounds and amines are important for cholinesterase inhibition. Finally, the model was deployed as a publicly available webserver called the ABCpred at http://codes.bio/abcpred/ .
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Acetylcholinesterase; Alzheimer’s disease; Anti-cholinesterase; Bioinformatics; Butyrylcholinesterase; Cholinesterase inhibitors; Data science; Machine learning

Mesh:

Substances:

Year:  2021        PMID: 34609711     DOI: 10.1007/s11030-021-10292-6

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   2.943


  60 in total

Review 1.  Drug development for Alzheimer's disease: review.

Authors:  Kejing Lao; Naichun Ji; Xiaohua Zhang; Wenwei Qiao; Zhishu Tang; Xingchun Gou
Journal:  J Drug Target       Date:  2018-06-20       Impact factor: 5.121

2.  Substrate binding to the peripheral site of acetylcholinesterase initiates enzymatic catalysis. Substrate inhibition arises as a secondary effect.

Authors:  T Szegletes; W D Mallender; P J Thomas; T L Rosenberry
Journal:  Biochemistry       Date:  1999-01-05       Impact factor: 3.162

Review 3.  Cholinesterases: new roles in brain function and in Alzheimer's disease.

Authors:  Ezio Giacobini
Journal:  Neurochem Res       Date:  2003-04       Impact factor: 3.996

Review 4.  Alzheimer's disease.

Authors:  C A Lane; J Hardy; J M Schott
Journal:  Eur J Neurol       Date:  2017-10-19       Impact factor: 6.089

5.  Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase.

Authors:  M Harel; I Schalk; L Ehret-Sabatier; F Bouet; M Goeldner; C Hirth; P H Axelsen; I Silman; J L Sussman
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

Review 6.  Current status on Alzheimer disease molecular genetics: from past, to present, to future.

Authors:  Karolien Bettens; Kristel Sleegers; Christine Van Broeckhoven
Journal:  Hum Mol Genet       Date:  2010-04-13       Impact factor: 6.150

7.  The 'aromatic patch' of three proximal residues in the human acetylcholinesterase active centre allows for versatile interaction modes with inhibitors.

Authors:  N Ariel; A Ordentlich; D Barak; T Bino; B Velan; A Shafferman
Journal:  Biochem J       Date:  1998-10-01       Impact factor: 3.857

Review 8.  Rational design of reversible acetylcholinesterase inhibitors.

Authors:  X Barril; S G Kalko; M Orozco; F J Luque
Journal:  Mini Rev Med Chem       Date:  2002-02       Impact factor: 3.862

9.  Fractional diffusion-limited component of reactions catalyzed by acetylcholinesterase.

Authors:  M Bazelyansky; E Robey; J F Kirsch
Journal:  Biochemistry       Date:  1986-01-14       Impact factor: 3.162

Review 10.  Alzheimer's disease hypothesis and related therapies.

Authors:  Xiaoguang Du; Xinyi Wang; Meiyu Geng
Journal:  Transl Neurodegener       Date:  2018-01-30       Impact factor: 8.014

View more
  2 in total

1.  Insight into potent TLR2 inhibitors for the treatment of disease caused by Mycoplasma pneumoniae based on machine learning approaches.

Authors:  Muhammad Ishfaq; Ziaur Rahman; Muhammad Aamir; Ihsan Ali; Yurong Guan; Zhihua Hu
Journal:  Mol Divers       Date:  2022-04-29       Impact factor: 2.943

2.  Setomimycin as a potential molecule for COVID‑19 target: in silico approach and in vitro validation.

Authors:  Ravi S Manhas; Harshita Tiwari; Mateen Noor; Ajaz Ahmed; Jyoti Vishwakarma; Raja B M Tripathi; Ravishankar Ramachandran; Sreedhar Madishetti; Debaraj Mukherjee; Amit Nargotra; Asha Chaubey
Journal:  Mol Divers       Date:  2022-05-27       Impact factor: 3.364

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.